SI Results and Discussion

hNav1.5 channel residues forming the putative antiarrhythmic and local anesthetic drug binding site
Key amino acid residues forming the putative antiarrhythmic and local anesthetic drug binding site in DIIIS6 and DIVS6 segments (1-4) are identical between hNaV1.5 and eeNaV1.4 (SI Appendix, Fig. S2 ). For example, F1760 and Y1767 in the DIVS6 segment in hNaV1.5 (Fig. 1A ) are F1555 and Y1562 in eeNaV1.4, respectively. Moreover, L1462 and I1466 in the DIIIS6 segment in hNaV1.5 (Fig. 1A ) are L1256 and I1260 in eeNaV1.4, respectively.
hNav1.5 channel residues forming the drug access pathway at the fenestration between the DIIIS6 and DIVS6
I1756 in the DIVS6 segment in hNaV1.5 is also identical in eeNaV1.4 (I1551) and forms part of the drug access pathway at the fenestration between the DIIIS6 and DIVS6 segments (see SI Appendix, Fig. S2 ) (2) . However, another key amino acid residue in the drug access pathway at the fenestration between DIIIS6 and DIVS6 segments (5) is different between hNaV1.5 and eeNaV1.4: T1753 in the DIVS6 segment of hNaV1.5 is C1548 in eeNaV1.4 (see Fig. 1B , SI Appendix, Figs. S2 and S3). Notably, T1753 is facing L1413 in the P1-helix of DIII, which is a unique residue in the fenestration between the DIIIS6 and DIVS6 segments because all other NaV channel domains have a Phenylalanine at the corresponding position (see SI Appendix, Figs. S3 and S4).
Modeling of antiarrhythmic and local anesthetic drugs interaction with human NaV1.5 channel using RosettaLigand.
QX-314 is a permanently charged derivative of lidocaine with a quaternary ammonium group. The most frequently sampled lowest binding energy RosettaLigand models of QX-314 interacting with hNav1.5 indicate that the region above F1760 in the DIVS6 segment forms a "hot spot" for QX-314 binding ( Fig. 2C and SI Appendix, Fig. S7 ), which is similar to the "hot spot" observed in our lidocaine -hNav1.5 models. The ammonium group of QX-314 is positioned above F1760 (Fig. 2C ). The phenyl ring of QX-314 is observed in multiple different orientations near F1760 ( Fig. 2C and SI Appendix, Fig. S7 ).
Etidocaine is a local anesthetic drug that was used in the first experimental study by the Catterall group that identified key residues of the receptor site for state-dependent block in both the DIVS6 segment (F1760 and Y1767 in hNaV1.5) (2) and the DIIIS6 segment (L1462 and I1466 in hNaV1.5) (4). The most frequently sampled lowest binding energy RosettaLigand models of charged etidocaine show the molecule binding above F1760 in the DIVS6 segment ( Fig. 2D and SI Appendix, Fig. S8 ), which is similar to the "hot spot" observed in our lidocaine and QX-314 -hNav1.5 models. The ammonium group of etidocaine is positioned above and near F1760 (Fig. 2D ). The phenyl ring of etidocaine is observed in multiple different orientations near F1760 ( Fig. 2D and SI Appendix, Fig. S8 ).
Neutral and charged lidocaine partitioning into the membrane
The molecular docking calculations provided us with atomistic structural models of convergent binding poses of several anti-arrhythmic and local anesthetic drugs in the hNaV1.5 pore (see Figs. 2 and 3 ). However, static molecular models cannot tell us how a drug accesses the binding site and whether such drug -protein interactions are long-lived or transient. Such information can be provided by atomistic molecular dynamics (MD) simulations of a channel embedded in a hydrated lipid membrane with one or multiple drug molecules present. To perform such simulations, we need accurate atomic-resolution structural models, called empirical force fields, for all the system components. For this study, we used biomolecular and generalized all-atom CHARMM force fields as described in SI Appendix and SI Methods.
We focused the MD simulations on hNav1.5 interactions with charged and neutral forms of lidocaine. This widely used antiarrhythmic and local anesthetic drug was chosen for our exploratory MD study because molecular docking calculations and previous experimental data indicate that it shares the same binding site as larger NaV1.5 blockers such as flecainide and ranolazine. Our previous MD simulation study of drug -bacterial Nav channel interactions suggested that we can more efficiently predict entry and egress pathways for a smaller drug, like the local anesthetic benzocaine, compared to the larger anti-epileptic drug phenytoin (6) . Indeed, experimental data indicate that lidocaine has faster NaV1.5 association and dissociation kinetics than the larger flecainide (7) . Moreover, in aqueous solution lidocaine exists as a mixture with a substantial fractions of both charged (~78% at pH=7.4) and neutral form (~22% at pH=7.4) which have different membrane permeabilities and can interact with the ion channels via distinct pathways, as was discussed above. Previous experimental and simulation studies suggested that charged and neutral forms of lidocaine differently affect NaV channel function (7) (8) (9) . Therefore, in this study we have explored charged and neutral lidocaine -lipid membrane and NaV1.5 interactions via all-atom MD simulations.
We developed force field parameters for charged and neutral lidocaine, because they are not available in the standard biomolecular (10, 11) or generalized CHARMM force field (CGENFF) (12) . We used gas-phase quantum mechanical (QM) drug geometries, vibrational frequencies, dihedral angle profiles, dipole magnitude and direction as well as interactions with water in different orientations as reference values for the parameter development, as described in SI Appendix SA1 and illustrated in SI Appendix, Figs. S11 and S12 and Tables S1-S3.
Lidocaine free energy profiles, used to obtain our logD estimate using Eq. 2 below are shown in SI Appendix, Fig. S13 and demonstrate that there is a higher barrier for charged vs. neutral lidocaine translocation across a lipid membrane in agreement with a previous study using different drug models (8) . However, contrary to ~5 kcal/mol free energy well at the membrane center for neutral lidocaine in that study (8) , our simulations predict an interfacial minimum of -1.09 kcal/mol at |z| = 13 Å and a ~4.64 kcal/mol peak at the membrane center (SI Appendix, Fig. S13 ). We also obtained even more favorable interfacial binding of -3.07 kcal/mol at |z| = 15 Å for charged lidocaine, which despite a larger peak of 6.58 kcal/mol at the membrane center leads to a more favorable membrane partitioning of this form. The partitioning coefficients for neutral and charged lidocaine forms computed using Eq. (1) below, were logK0 = 0.12 +/-0.40 and logK1 = 1.35 +/-0.14 respectively. Experimentally, logK0 has been measured to be in the range of 2.1 to 2.39 (13) , while logK1 has been measured in the range 0.9 to 1.49 (13) depending on the experimental conditions. The distribution coefficient log D = 1.25 ± 0.32 computed using Eq. (2) below was fairly consistent with experimental values of 1.4 (14) and 1.76 (13) , despite an underestimated partition coefficient for the neutral form of the drug since the charged form is dominant at physiological pH. We also used an approximation of Kramer's transition rate theory to estimate the transition rates (15, 16) of charged and neutral forms of lidocaine through a simulated POPC bilayer. We used the same approach as in our previous study (17) and for charged and neutral lidocaine computed their diffusion coefficients (18) close to the membrane center using Hummer's method, as well as the curvatures around the binding wells and peaks (i.e. free energy minima and maxima) , estimated from second derivatives of second-order polynomial fits to the relevant portion of each respective free energy profile. Estimated transition rates through the membrane are 38.9 s -1 for charged lidocaine and 21.1ms -1 for the neutral drug form, indicating three orders of magnitude faster crossing rate for the latter.
Since charged lidocaine is the dominant drug form at a physiological pH 7.4 (~78.4% based on its pKa = 7.96) (14) , we primarily expect the accumulation of charged drug at water-membrane interfaces, in agreement with recent solid NMR experiments (19) . However, deeper into the hydrophobic membrane core, neutral lidocaine is expected to be the more dominant form and should be able to translocate across a membrane more easily due to the substantially smaller barrier than its protonated counterpart (~6 kcal/mol vs. ~10 kcal/mol) (SI Appendix, Fig. S13 ). This indicates that we need to study both charged and neutral lidocaine interactions with hNaV1.5 to assess hydrophobic (lipid-mediated access through channel fenestrations) and hydrophilic (water-mediated access through an intracellular gate) channel pore drug access pathways and understand molecular mechanisms of channel activity modulation.
SI Methods
Rosetta modeling of the hNaV1.5 channel
We used the Rosetta structural modeling software (20) (21) (22) and the cryoEM structure of the NaV1.4-beta1 complex from the electric eel (eeNaV1.4) (PDB ID: 5XSY) as a template to predict the structure of the human NaV1.5 (hNaV1.5) channel. At first, the structure of eeNaV1.4 without the beta1 subunit was passed through the Cryo-EM refinement protocol in Rosetta (23) . The lowest scoring density-refitted eeNaV1.4 model and electron density were then used in combination in RosettaCM (24) to model the hNaV1.5 channel. We generated 5,000 structural models of hNaV1.5 and selected the top 500 lowest-scoring models for clustering analysis as described previously (25) . Models from top clusters were visually inspected to select the final model for the docking study.
RosettaLigand modeling of hNaV1.5 channel interaction with antiarrhythmic and local anesthetic drugs
OpenEye OMEGA (OpenEye Scientific Software) (26, 27) was used to generate conformers for antiarrhythmic and local anesthetic drugs. To uniformly and efficiently sample the pore region of hNaV1.5, drugs were placed at 5 different initial locations: at the center of the cavity and at 4 fenestration sites. We incorporated an initial random perturbation with a translation distance less than 10 Å before the docking run to add another layer of randomization. Sampling radius was set to 10 Å. The details of the RosettaLigand docking algorithm have been described previously (20, 28-31) (see Rosetta scripts and command lines used in Appendix SA1). A total of 200,000 docking models were generated for each drug. The top 10,000 models were selected based on the total score of proteinligand complex and then ranked by ligand binding energy represented by Rosetta interface delta_X energy term. The top 50 ligand binding energy models were visually analyzed using UCSF Chimera (32) 
Drug forcefield parameterization
We obtained the molecular structure of lidocaine from the ZINC database (accession number 20237), (33) , and used the CGENFF program, version 1.0 (34, 35) to generate initial guesses for partial atomic charges, bond lengths, bond angles, and dihedral angles.
The initial topology and parameters for charged and neutral forms lidocaine were subsequently validated and optimized using QM target data following the suggested CGENFF force field methodology (36) . High-quality parameters not already present in CGENFF are assigned from existing parameters based on chemical analogy, and our optimizations focused on parameters with poor chemical analogy corresponding to a high penalty score (35) . The Force Field Toolkit plugin (ffTK) (37) for the Visual Molecular Dynamics program (VMD) (38) was used to generate files for quantum mechanical (QM) reference calculations and to perform parameter optimizations. QM target data for parameter optimization were obtained utilizing Møller-Plesset (MP2) and Hartree-Fock (HF) electronic structure methods and the 6-31(d) basis set using the Gaussian 09 program (39) . MP2/6-31G(d) molecular dipole magnitude and orientation as well as scaled HF/6-31G(d) interaction energies with water were used for the optimization of partial atomic charges compatible with the CHARMM atomistic force fields (40) . Internal bond and angle parameters were validated by comparison to MP2/6-31G(d) optimized geometries and scaled vibrational frequencies, and differences within 0.01 Å and 1° between QM and MM equilibrium bond and angle values were sought. Finally, the dihedral angle parameters were optimized to reproduce MP2/6-31G(d) potential energy scans for rotation around a particular bond.
Optimized charges (Table S1 ) are in good agreement with QM target dipole values. The optimized MM dipole moments are overestimated in magnitude from QM MP2/6-31G(d) dipole moments by 17% for neutral lidocaine and 16% for charged lidocaine (close to a 20% acceptable lower-end threshold, suggested for the CGENFF force field), and the MM dipole direction differed by ~1° from the QM computed direction for both charged and neutral lidocaine. The water interaction distances were all within 0.4 Å of QM target values (see Tables S2 and S3 ). The MM dipole moment for charged lidocaine (11.7 Debye) is ~3 times higher than for neutral lidocaine (3.9 Debye), which agrees with respective computed QM values. Water interaction energies were also in good agreement with QM values, with root mean squared errors (RMSE) of 0.95 kcal/mol for neutral lidocaine, and 1.41 kcal/mol for charged lidocaine, respectively (Table S4) . For neutral lidocaine, there was a high penalty score for the C2-N1-C3 bond angle, and optimization yielded a difference of 0.16° between MM and QM values. For charged lidocaine there were no high penalties for internal bond and angle parameters from the CGENFF. For neutral lidocaine, there were four high-penalty dihedral angles, and for charged lidocaine there were two high-penalty dihedral angles from the CGENFF. Dihedral optimizations resulted in great improvement over CGENFF initial guesses (illustrated SI Appendix, Figs. S11 and S12), with optimized torsional energy minima within ~2 kcal/mol of QM values. For comparison, raw CGENFF dihedral parameters with high penalties yielded QM free energy minima differences sometimes as high ~5kcal/mol.
Final topology and parameters for neutral and charged lidocaine are provided in the Appendix SA2.
Drug-membrane partitioning
Partitioning of charged and neutral lidocaine into a lipid membrane was assessed using the NAMD (41) program. Initial system setup scripts were generated with the CHARMM-GUI web toolkit (42) and were modified to build the hydrated drug-membrane systems, which consisted of 128 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) lipids, ~7000 water molecules, 21 or 22 K + and 22 Clions to ensure 0.15 M electrolyte concentration and overall electrical neutrality, and one drug molecule, totaling ~38,250 atoms. CHARMM36 lipid force field (10), TIP3P water model (43), standard CHARMM ion parameters (44) and CGENFF (12) compatible drug parameters developed in this work were used throughout all simulations.
For partitioning calculations of each drug we used the umbrella sampling (US) method (45) with 81 independent simulation windows, placing the center of mass (COM) of a randomly oriented drug molecule in 1 Å intervals from -40 Å to 40 Å with respect to COM of the membrane. The COM of the drug was restrained along the z axis with a force constant of 2.5 kcal/mol/Å 2 , and an additional 5 kcal/mol/Å 2 cylindrical restraint was applied in order to prevent the drift of the molecule in the xy plane. Each NAMD US simulation of charged and neutral lidocaine was carried out in a NPT ensemble with 1 atm pressure maintained by Langevin piston barostat (46) , and 310K, controlled by Nosé-Hoover thermostat (47, 48) . Tetragonal cells with periodic boundary conditions (PBC) were used in all the simulations, and the SHAKE algorithm (49) was employed to fix the bonds to all hydrogen atoms, allowing for the use of a 2 fs time step. Electrostatic interactions were computed via Particle Mesh Ewald (50), with a mesh grid of 1 Å.
Potential of mean force (PMF) profiles were computed using the weighted histogram analysis method (WHAM) (51) . Umbrella sampling simulations for charged and neutral lidocaine were run for 15 ns per window. Standard errors in PMFs were computed as a measure of asymmetries with respect to the membrane center (z=0).
Drug-water partition coefficients were calculated as was done previously (52):
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is the PMF, z1 and z2 are points in aqueous solution on opposite sides of the membrane, kB is Boltzmann constant, and T is the absolute temperature.
The distribution coefficient, log D, was computed as log = log( ( + * 10 -./0-1 ) − log(1 + 10 -./0-1 ) (2) where K0 is the partition coefficient of a neutral drug form, and K1 is the partition coefficient of a charged (protonated) drug form (13) . Standard errors for log K and log D were estimated from asymmetries in free energy profiles via propagation of uncertainties.
To compute drug translocation rates across membrane we used Kramer's transition rate approximation as was done previously (15, 16) . For charged lidocaine local diffusion near the membrane center was computed to be D(zbarrier)=0.0047 Å 2 /ps, and the curvatures of the PMF well and the PMF peak were 0.0508 and -0.207, respectively. For neutral lidocaine D(zbarrier)=0.0089 Å 2 /ps, and the curvatures of the PMF well and the PMF peak were 0.0312 and -0.0784, respectively.
Molecular dynamics simulations of hNaV1.5 channel interaction with lidocaine
The hNaV1.5 model was embedded in a bilayer of POPC with explicit TIP3P water molecules and 150 mM (with lidocaine) or 500 mM (without lidocaine) of NaCl using CHARMM-GUI (53) . For lidocaine containing simulations we used physiological NaCl concentration, but we used larger salt concentration in the drug-free runs to facilitate Na + conductance. For all these simulations, we also used CHARMM36 lipid (54) and protein (11) force fields, and CHARMM generalized force field (CGENFF) compatible parameters for lidocaine as described above. Initial system equilibrations were performed using NAMD on a local GPU cluster. After 10,000 steps of steepest descent minimization, MD simulations started with a timestep of 1 fs with harmonic restraints initially applied to protein heavy atoms and some lipid tail dihedral angles. These restraints were slowly released over 2 ns. Harmonic restraints (0.1 kcal/mol/Å 2 ) were then applied only to protein Ca atoms, and the systems were equilibrated further for 50 ns with a timestep of 2 fs. In order to use a 2 fs timestep, all bonds to H atoms were constrained using the SHAKE algorithm. All simulations were performed at constant pressure (1 atm) with constant ratio of x and y dimensions in order to maintain the correct area per lipid, and constant temperature of 303.15 K (chosen to avoid the gel phase transition of POPC lipids). Electrostatic interactions were computed using Particle Mesh Ewald (PME). Non-bonded pair lists were updated every 10 steps with a list cutoff distance of 16 Å and a real space cutoff of 12 Å with energy switching starting at 10 Å.
Equilibrated systems were simulated on the Anton 2 supercomputer using Anton 2 software (55) version 1.31.0 in the NPT ensemble at 303.15 K. A 2 fs timestep was used with nonbonded long-range interactions computed every 6 fs using the RESPA multiple time step algorithm. The multi-integrator (multigrator) algorithm was used for temperature and semiisotropic pressure coupling. Long-range electrostatic interactions were handled by u-series algorithm (55) . A long-range Lennard-Jones (LJ) correction (beyond cutoff) was not used as was suggested for CHARMM36 lipid force field. For the simulation of hNaV1.5 without drugs, an electric field was applied downwardly in the z direction to mimic membrane potential of 250 mV (positive inside).
For the neutral lidocaine simulations, two different systems were created with initial neutral lidocaine aqueous concentration at 75mM and 150mM. Each system was simulated for 7 µs on Anton2.
For the charged lidocaine simulations, systems of 1 and 2 charged lidocaine were created by initially placing 1 and 2 charged lidocaine molecules in the cavity of the hNav1.5 model. Each system was simulated for 1 µs on Anton2.
Analysis
Drug binding in the channel: 3D density maps of the drug center of mass for the neutral lidocaine and position of the amino group for the charged one from NaV1.5 -drug flooding MD simulations were used to compute free energy profiles using equation W(ri) = -kBTln[r(ri)] + C where r(ri) is the unbiased probability distribution as a function of reaction coordinates ri, and C is a constant. The maps were offset to get an average free energy of 0 kcal/mol in bulk water for neutral lidocaine or for the binding site in the pore for the charged lidocaine. 2D projections of these free energy maps on the Z (transmembrane) and Y (lateral) axes are shown in Figs. 4, 5 and 6. Origin is selected as the center of mass of the protein.
Sodium binding in the selectivity filter ( Fig. 7) : xy-radial position ≤ 15Å, and z-axial position between -15 and +15 Å were used to define the pore region for ion occupation. Table S3 Movie S1. Molecular dynamics simulation of hNav1.5 channel interaction with lidocaine reveals hydrophilic drug access pathway. Transmembrane view of hNav1.5 channel model (colored in light gray) with sidechains of F1760 and Y1767 shown in stick representation. Lidocaine molecule that accessed the pore lumen through the intracellular gate is shown in spacefilling representation and colored in cyan with nitrogen atoms colored in blue and oxygen atom colored in red. The pore-forming domains I and IV are shown in the front view during the first half of the movie. The pore-forming domains III and IV are shown in the front view during the second half of the movie.
Movie S2. Molecular dynamics simulation of hNav1.5 channel interaction with lidocaine reveals hydrophobic and hydrophilic drug access pathways. Transmembrane view of hNav1.5 channel model (colored in light gray) with sidechains of F1760 and Y1767 shown in stick representation. Lidocaine molecule that accessed the pore lumen through the fenestration between domains III and IV is shown in spacefilling representation and colored in cyan with nitrogen atoms colored in blue and oxygen atom colored in red. Lidocaine molecule that accessed the pore lumen through the intracellular gate is shown in spacefilling representation and colored in purple. Side chains of residues that form hydrophobic access pathway for lidocaine are shown in stick representation and colored in dark gray. The pore-forming domains III and IV are shown in the front view during most of the movie. The pore-forming domains I and IV are shown in the front view at the end of the movie.
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